



ERIC HOLCOMB, GOVERNOR  
STATE OF INDIANA

*Office of Medicaid Policy and Planning*  
MS 07, 402 W. WASHINGTON STREET, ROOM W382  
INDIANAPOLIS, IN 46204-2739

## MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

November 1, 2024

9:00 A.M. EST

### Hybrid Meeting

Conference Center Room C

Indiana State Government Center South

Virtual Meeting Information Below

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of August 2, 2024
4. Preferred Drug List: Therapeutic Class Re-Review
  - a) CNS and Others
    - i. Agents for the Treatment of Opioid Use Disorder or Overdose
    - ii. Antiemetic/Antivertigo Agents
    - iii. Antiseizure Agents
    - iv. Gastroprotective Agents
    - v. Movement Disorder Agents
    - vi. Narcotic Antitussives and Combinations
    - vii. Narcotics
    - viii. Skeletal Muscle Relaxants
    - ix. Smoking Deterrent Agents
  - b) Dermatologic Agents
    - i. Acne Agents



- ii. Antipsoriatics
- c) Endocrine
  - i. Anaphylaxis Agents
  - ii. Bone Formation Stimulating Agents
  - iii. Bone Resorption Inhibitors
  - iv. DPP-4 Inhibitors and Combination Agents
  - v. GLP-1 Receptor Agonists and Combinations
  - vi. Glucagon Agents
  - vii. Growth Hormones
  - viii. Insulins
  - ix. Miscellaneous Oral Antidiabetic Agents
  - x. SGLT Inhibitors and Combinations
  - xi. Testosterones
  - xii. Urea Cycle Disorders (Hyperammonemia Treatments)
- d) Estrogen and Related Agents
  - i. Estrogen and Related Agents
  - ii. Contraceptives
- e) Gastrointestinal Agents
  - i. Anti-ulcer Agents
  - ii. *H. Pylori* Agents
  - iii. H2 Receptor Antagonists
  - iv. Laxatives and Cathartics
  - v. Pancreatic Enzymes
  - vi. Proton Pump Inhibitors
  - vii. Ulcerative Colitis Agents
- f) Genitourinary Agents
  - i. Benign Prostatic Hypertrophy Agents
  - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g) Hematologic Agents
  - i. Direct Oral Anticoagulants
  - ii. Hematinics

- iii. Leukocyte (WBC) Stimulants
- iv. Platelet Aggregation Inhibitors
- h) Topical Agents
  - i. Dry Eye Disease or Keratoconjunctivitis
  - ii. Miotics-Intraocular Pressure Reducers
  - iii. Ophthalmic Antihistamines
  - iv. Ophthalmic Anti-Inflammatory Agents
  - v. Ophthalmic Mast Cell Stabilizers
  - vi. Otic Preparations
  - vii. Topical Anti-Inflammatory Agents-NSAIDs
  - viii. Topical Antiparasitics
  - ix. Topical Immunomodulators
  - x. Topical Post-herpetic Neuralgia Agents
- i) Drug Classes for SUPDL Consideration
  - i. Antivirals-HIV Agents
- 5. New Business
- 6. Public Comment
- 7. Other Business
- 8. Adjourn

---

## Microsoft Teams meeting

### **Join on your computer, mobile app or room device**

[Click here to join the meeting](#)

Meeting ID: 262 463 242 400

Passcode: 7bnhnp

[Download Teams](#) | [Join on the web](#)

### **Join with a video conferencing device**

425899727@t.plcm.vc

Video Conference ID: 113 407 099 74

[Alternate VTC instructions](#)

### **Or call in (audio only)**

[+1 952-222-7450,,676941924#](#) United States, Bloomington

Phone Conference ID: 676 941 924#

[Find a local number](#) | [Reset PIN](#)